Who
John T. Henderson
Director
Company insider
Files Form 4 as: Director, Cytokinetics; Director, Myriad Genetics; Director, Myrexis.
In numbers
- Trades disclosed
- 215
- Buys
- 5
- Sells
- 23
- Bought
- $337K
- Sold
- $13.1M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 6 Jan 2006
- Last trade
- 15 Jul 2026
- Last filed
- 16 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jul 2026filed 16 Jul 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $22K272 at $82.62 | filing |
| 15 Jul 2026filed 16 Jul 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $22K272 at $82.62 | filing |
| 27 May 2026filed 27 May 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | —2,851 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,301 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,301 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | —2,851 at $0.00 | filing |
| 5 May 2026filed 5 May 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code M | $152K20,000 at $7.61 | filing |
| 5 May 2026filed 5 May 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $1.5M20,000 at $75.97 | filing |
| 5 May 2026filed 5 May 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 5 May 2026filed 5 May 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 5 May 2026filed 5 May 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code M | $152K20,000 at $7.61 | filing |
| 5 May 2026filed 5 May 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $1.5M20,000 at $75.97 | filing |
| 15 Apr 2026filed 15 Apr 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $21K325 at $65.37 | filing |
| 15 Apr 2026filed 15 Apr 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $21K325 at $65.37 | filing |
| 15 Jan 2026filed 16 Jan 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $21K334 at $63.44 | filing |
| 15 Jan 2026filed 16 Jan 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $21K334 at $63.44 | filing |
| 2 Dec 2025filed 2 Dec 2025 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,750 at $0.00 | filing |
| 2 Dec 2025filed 2 Dec 2025 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code M | $88K8,750 at $10.00 | filing |
| 2 Dec 2025filed 2 Dec 2025 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $559K8,750 at $63.90 | filing |
| 15 Oct 2025filed 16 Oct 2025 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $21K338 at $62.80 | filing |
News
Head to Head Survey: Maze Therapeutics (NASDAQ:MAZE) vs. Cytokinetics (NASDAQ:CYTK)CYTK · dailypolitical.com · 18 Oct 2026Head to Head Comparison: Cytokinetics (NASDAQ:CYTK) vs. Pluri (NASDAQ:PLUR)CYTK · themarketsdaily.com · 10 Oct 2026Cytokinetics (NASDAQ:CYTK) EVP Sells 3,500 Shares of StockCYTK · themarketsdaily.com · 6 Oct 2026
0 headlines in the last 90 days name John T. Henderson; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.